|
|
||||||||
Articles |
1
Quest Diagnostics Inc., 1 Malcolm Ave., Teterboro, NJ 07608-1070;
2
Wallingford, CT 08492; and
3
Horsham, PA 19044.
4
Centers for Disease Control and Prevention,
Atlanta, GA 30341.
a Author for correspondence. Fax 201-393-5903; e-mail Doclab{at}aol.com
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The relation between the two measurements, however, could vary a great deal if iron binds to other proteins to any significant degree, or if the binding of iron to TRF is altered as iron concentrations change, or if either assay has poor precision or bias, or both.
Several articles suggest that, contrary to theory, the relation between TIBC and TRF is not fixed, especially when results are outside the reference range (4)(5). The reported mean ratio between TIBC and TRF has ranged from a low of 11.3 to a high of 26.1 (6)(7).
We undertook this multilaboratory study of the relation between TIBC and TRF to investigate these discrepancies.
| Design of Experiments |
|---|
|
|
|---|
The UIBC assay is essentially identical on each of these high-throughput chemistry analyzers. A precisely known amount of iron in solution is added to diluted serum. The added iron binds to previously unsaturated binding sites on TRF. After a short time<5 minthe amount of iron that did not bind to TRF is measured colorimetrically. UIBC is defined as the difference in the color produced by the original amount of added iron (highest color) and the color produced by the residual iron in solution that did not bind to TRF (less color).
TRF was measured immunologically on either the Behring Nephelometer II
(Behring Diagnostics) or the Beckman Array® 360-CE
(Beckman Instruments), or both, with respective calibrators from
Behring or Beckman. The calibrators were standardized to the IFCC's
preparation for plasma proteins Clinical Reference Material lot 470,
which was certified by the Bureau of Reference of the European
Community and designated the Reference Preparation for Proteins in
Human Serum by the College of American Pathologists. This new
calibrator yields TRF concentrations that are 13% lower than those
obtained with the older calibrator. Table 1
specifies the nephelometer used and in which laboratory. The
two nephelometers differ in how they measure the protein
concentrations. The Beckman Array monitors the rate at which scattered
light changes. The Behring nephelometer measures the amount of light
scattered at a defined end point.
|
precision studies
Two independent precision studies were conducted: one in March
1996 in the Wallingford laboratory, and one in October 1996 in the
Teterboro laboratory. In each study, human serum pools were assayed in
duplicate once daily for 20 days. The Wallingford study used three
pools: one with a low TIBC concentration (~30 µmol/L), one with a
normal TIBC concentration (~50 µmol/L), and one with a high TIBC
concentration (~70 µmol/L). The Teterboro study used two pools: one
with a saturation of TRF <15%, and one with a saturation of TRF
>50%. All pools were generated from discarded samples of serum that
had been separated from cells by centrifugation of a barrier tube soon
after blood had been collected. Once assembled, each pool was aliquoted
into multiple 5-mL plastic vials and stored frozen (-30 °C) until
used.
bias studies
Bias was assessed in two independent experiments (April 1996 and
January 1997). In each experiment, three frozen reference pools (9114,
9115, and 9116) were obtained from the CDC. The TIBC and serum iron
concentrations of each pool were previously defined by CDC with a
reference AutoAnalyzer method (8) based on the procedures
of Giovanniello et al. (9) and of Ramsey
(10). We measured the TRF concentration of each pool
immunologically on Behring and Beckman equipment at the Teterboro and
Wallingford laboratories, respectively. The pools were also assayed
colorimetrically on Olympus equipment at the Teterboro and Wallingford
laboratories.
patient sample selection
We studied 570 serum samples from 491 patients. Study samples were
selected from serum samples submitted for analysis of iron and TIBC
concentrations to each of the three laboratories (Teterboro, Horsham,
and Wallingford) in the Quest Diagnostics laboratory network (formerly
Corning Clinical Labs.). Samples were specially selected to include a
wide range of TIBC and TRF concentrations as well as high and low
percent saturation of TRF with iron. Three independent studies of
patient samples were conducted at the Teterboro laboratory over 13
months; one study was conducted at the Horsham laboratory over 2 weeks,
and one study was conducted at the Wallingford laboratory where 72
samples were assayed for TRF by the Beckman immunologic assay; 52 of
the 72 were also assayed for TRF by the Behring immunologic assay.
Patient samples from the Horsham and Wallingford laboratories were also
analyzed for TIBC and TRF at the Teterboro laboratory.
Table 1
lists the selection criteria used in each of the five studies,
and Table 2
lists the range of values for TRF and TIBC, percent saturation
of TRF, and the ratios of TIBC to TRF encompassed by the five studies.
The mean ratio of TIBC to TRF for 567 patient samples (570 - 3
outliers) was 22.3not the ideal ratio of 25.0. The TIBC/TRF ratio of
the 567 samples ranged from a low of 17.6 to a high of 29. This wide
range can be attributed to the inherent imprecision of Behring's
immunoassay for TRF, and to the unavailability of standardized
human-based calibrators for UIBC. The TIBC/TRF ratios of the three
outliers were 15.2, 13.8, and 10.0; the TIBC concentrations were 43.7,
36.5, and 41.0 µmol/L; and the TRF concentrations were 2.87, 2.64,
and 4.09 g/L, respectively.
|
| Results |
|---|
|
|
|---|
bias
When CDC's target values for TIBC were muliplied by 25.0
we obtained a theoretical TRF concentration that was in close agreement
with the immunologically measured TRF concentration as shown in Table 3
. For the three pools, the ratio of CDC's target concentration
for TIBC to our measured TRF concentration ranged from a low of 23.6 to
a high of 24.7. This is close to the theoretically expected ratio of
25.0, and confirms the validity of using the concentration of TRF to
check the bias of the TIBC assay. Similar results were obtained in two
separate studies that were 10 months apart. Each study was carried out
in two laboratories. Table 3
also demonstrates that all laboratories
that follow current Hitachi and Olympus recommendations for measuring
UIBC are underestimating TIBC by ~814% when compared with expected
values based on CDC reference pools. This a generic problem with the
manufacturers' methods and with currently available calibrators from
manufacturers. The individual data points in these bias experiments
also reconfirmed the higher imprecision of the Behring immunoassay for
TRF when compared with the Beckman immunoassay.
|
patient correlations
Figure 1
is a scatter plot of 567 comparisons of TIBC by colorimetric
assay and TRF by Behring nephelometric immunoassay, representing the
combined results of five independent experiments in three laboratories.
Three outliers were excluded. The correlation between TIBC measured
colorimetrically and TRF measured immunologically over a wide range of
values is high: r2 = 0.941.
|
We estimated the contributions of the variances of the TIBC and TRF assays to the total variance of the scatter plot as follows:
The SE of predicted y from x =
Sy|x = 3.57; the mean for
y = 57.8 µmol/L
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Figure 2
is a scatter plot of the results of 72 comparisons
of TIBC by colorimetric assay and TRF by Beckman nephelometric
immunoassay. The correlation is improved when TRF is assayed with the
more precise Beckman assay: r2 = 0.968.
|
| Discussion |
|---|
|
|
|---|
There is wide scatter in literature-reported ratios of TIBC to TRF, ranging from a low of 11.3 (5) to a high of 34.4 (4). Only two (1)(11) of six other studies (1)(3)(7)(11)(12)(13) reported ratios close to 25.0 (i.e., 24.4 (1) and 23.3 (11)), and then only when results in the older study (1) were corrected by us to be equivalent to those obtained with the new IFCC TRF standard. Most significant in our analysis of these disparate ratios is the high proportion of observations that differ from ideal when radial immunodiffusion was used as the immunologic method for TRF. Manual radial immunodiffusion methods are not as precise as automated nephelometric methods (1).
Indeed, our results and our review of published articles suggest that any reported deviation from the theoretically expected ratio of 25.0 between TIBC and TRF indicates a problem with either or both assays. Moreover, unless precise and unbiased TIBC and TRF methods are used, identifying a genuine occurrence of "deviant" TRF or TIBC will be impossible.
The results we obtained for the CDC pools with our colorimetric UIBC assay on Hitachi and Olympus equipment suggest a manufacturer-related error in the calibration of the UIBC channel, but not of the serum iron channel.
We studied the effect of changes in ferritin, percent saturation of
TRF, UIBC, and TIBC on the ratio of TIBC measured colorimetrically to
TRF measured on the more precise Beckman nephelometer and found that
there is about a 10% difference in the ratio between the lowest and
highest values of the variables studied. Table 4
summarizes our findings. The highest ratios were found when
ferritin was high, when percent saturation was high, when UIBC was low,
and when TIBC was low. There is some selection bias in the ferritin
data because only 52 of the 72 samples had a ferritin test, and 27 of
the 52 ferritin concentrations were >1000 µg/L. There is a common
denominator, however, among all of these variables: the number and
availability of binding sites for iron on TRF. When ferritin
concentrations are increased, the percent saturation of TRF is usually
also high and available binding sites are decreased. When the number of
unsaturated binding sites decreases, less time is required for the
reaction to approach completion, which results in reporting a higher
UIBC concentration, a higher TIBC concentration, and a higher ratio of
TIBC to TRF. Conversely, when the number of unsaturated binding sites
increases, more time is required for the reaction to approach
completion, which is the case when percent saturation and ferritin
concentrations are low, and when UIBC and TIBC concentrations are high.
|
Our results suggest that TRF-containing protein-based calibrators should be used for the primary calibration of Hitachi and Olympus UIBC. A preliminary study of calibration methods at our Teterboro laboratory confirms the superiority of two-point calibration with human serum. Two-point calibration of the UIBC channel with the low and high reference pools from CDC, rather than with an aqueous zero and a single-point commercially available bovine calibrator, yielded superior results. The mean ratio of TIBC to TRF was 24.6 when we assayed 29 different patient-derived minipools covering a wide range of TIBC concentrations. The spread of values for the ratio was very tight, ranging from a low of 23.5 to a high of 26.3, and the correlation of TIBC to TRF was high: r2 = 0.992. Moreover, two-point calibration of the UIBC channel with human serum eliminated the effect of UIBC concentrations on the ratio.
On the basis of these results, Quest Diagnostics is restandardizing all of its UIBC/TIBC methods to be in agreement with TRF concentrations measured immunologically. In addition, we are working with suppliers of reagents and calibrators to assist them in the development of unbiased secondary nonhuman calibrators for UIBC that are traceable to human-based primary calibrators. The UIBC/TIBC concentrations of the primary calibrators are defined by chemical reference methods and by TRF assays standardized to the IFCC's preparation for plasma proteins.
In summary, TIBC and TRF are equivalent when each is measured precisely and without bias.
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
The following articles in journals at HighWire Press have cited this article:
![]() |
A M Emara, R S El Kelany, and K A Moustafa Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats Human and Experimental Toxicology, July 1, 2006; 25(7): 375 - 385. [Abstract] [PDF] |
||||
![]() |
A. Van Campenhout, C. Van Campenhout, A. R. Lagrou, and B. Manuel-y-Keenoy Effects of in Vitro Glycation on Fe3+ Binding and Fe3+ Isoforms of Transferrin Clin. Chem., September 1, 2004; 50(9): 1640 - 1649. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yamanishi, S. Iyama, Y. Yamaguchi, Y. Kanakura, and Y. Iwatani Total Iron-binding Capacity Calculated from Serum Transferrin Concentration or Serum Iron Concentration and Unsaturated Iron-binding Capacity Clin. Chem., January 1, 2003; 49(1): 175 - 178. [Full Text] [PDF] |
||||
![]() |
H. Yamanishi, S. Iyama, Y. Yamaguchi, Y. Kanakura, and Y. Iwatani Modification of Fully Automated Total Iron-binding Capacity (TIBC) Assay in Serum and Comparison with Dimension TIBC Method Clin. Chem., September 1, 2002; 48(9): 1565 - 1570. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Siek, J. Lawlor, D. Pelczar, M. Sane, and J. Musto Direct Serum Total Iron-binding Capacity Assay Suitable for Automated Analyzers Clin. Chem., January 1, 2002; 48(1): 161 - 166. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. T. Goodnough, B. Skikne, and C. Brugnara Erythropoietin, iron, and erythropoiesis Blood, August 1, 2000; 96(3): 823 - 833. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |